Table 2:
Standardized Beta coefficient | P-value | |
---|---|---|
Demographic characteristics | ||
Mean age (SD) | −0.05 | 0.57 |
Female gender | 0.04 | 0.64 |
Clinical characteristics | ||
IBS subtype | 0.03 | 0.73 |
Mean IBS symptom severity | −0.13 | 0.13 |
Change in IBS severity over 3 months | −0.29 | 0.001* |
Baseline psycho-somatic characteristics | ||
Baseline anxiety score | −0.16 | 0.07* |
Baseline depression score | −0.24 | 0.005* |
Baseline sleep disturbance score | −0.06 | 0.49 |
Change in anxiety score | −0.12 | 0.18 |
Change in depression score | −0.11 | 0.23 |
Change in sleep score | −0.004 | 0.96 |
Baseline Healthcare utilization | ||
Prior gastroenterology consultation | −0.12 | 0.18 |
Duration of symptoms | 0.10 | 0.26 |
Healthcare utilization in three months | ||
Serological or stool investigations performed | 0.10 | 0.24 |
Number of diagnostic tests performed** | 0.28 | 0.001* |
Number of medications tried for GI symptoms*** | 0.05 | 0.60 |
Number of recommendations at initial visit**** | 0.19 | 0.03* |
Number of phone calls | −0.11 | 0.20 |
Number of gastroenterology follow-up visits | 0.20 | 0.02* |
Number of services referred to by gastroenterologist | 0.11 | 0.19 |
Physician characteristics | ||
Patients evaluated by female physician | −0.05 | 0.59 |
Patients evaluated by Fellows at first visit | −0.13 | 0.13 |
Factors with P-value less than 0.1 which were include in multivariable regression
Includes endoscopies, manometries, breath tests, and radiologic investigations
Includes over the counter as well as prescription
Includes pharmacological and non-pharmacological therapies, referrals, lifestyle changes